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ABSTRACT
Interleukin 17 (IL-17) promotes the expression of cytokines and proteins 
involved in inflammation response via the induction of gene transcription and 
post-transcriptional stabilization of mRNA. 
We  show  here  that  IL-17  enhanced  the  stability  of  zc3h12a mRNA 
through the RNA binding protein DDX3X. After receptor triggering DDX3X 
binds  the  ubiquitin  ligase  CIKS  trough  the  helicase  domain  and  stabilize 
zc3h12a mRNA by directly binding the mRNA. This process involved CIKS 
(but the E3 ubiquitin ligase function is dispensable) the adaptors TRAF2 and 
TRAF5, and the kinase IKKε. 
Zc3h12a  is  an  endonuclease  involved  in  controlling  inflammatory 
responses by degrading mRNA of some inflammatory protein such as IL-6. 
This  effect  is  important  to  correctly  switch-off  the  IL-17-dependent 
inflammation.
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BACKGROUND
TH17 linfocites
T  helper  17  cells  (Th17)  are  a  subset  of  T  helper  cells  producing 
interleukin  17  (IL-17)  developmentally  distinct  from  Th1  and  Th2 
cells(Harrington et al., 2005; Park et al., 2005)
Originally IL-17 was thought to be produced exclusively by T cells, but it 
is  now  known  to  be  secreted  by  a  variety  of  innate  cells  including 
macrophages, mast cells, dendritic cells, and natural killer(Korn et al., 2009).
Whereas it was known for decades that IL-12 induces Th1 cells (IFN-
producers) and IL-4 induces Th2 cells (IL-4, IL-5 and IL-13 producers), it was 
only  recently  demonstrated  that  Th17  cells  differentiate  upon  exposure  to 
combinations of IL-6 and transforming growth factor-β (TGF-β). 
Initial differentiation fase of mouse TH17 cells requires the presence of 
transforming  growth  factor-β  (TGFβ)  and  IL 6  as  well  as  STAT3‐  
signalling(Bettelli et al., 2007). Analogous to the differentiation of TH1 and 
TH2 cell lineages, TH17 cells require additional lineage-specific transcription 
factors.  Both  retinoid-related  orphan  receptor-α  (RORα)  and  RORγt  are 
required for TH17 cell  differentiation(Dong, 2008b),  and these transcription 
factors can be induced by the combined presence of TGFβ and IL 6 in naive T‐  
cells(Chung et al., 2009; Martin et al., 2009; Sutton et al., 2009). 
It  has  been  argued  that  differentiation  of  human  TH17  cells  could 
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Figure 1: General scheme of T-helper-cell differentiation. Nat Rev Immunol. 
2008 May; 8(5):337-48.
potentially occur independently of TGFβ, as a combination of IL 23 and IL 1β‐ ‐  
has been shown to be sufficient to induce TH17 cell differentiation. However, 
murine and human TH17 cells are very similar; both cell types express IL 17A,‐  
IL 17F, IL 21, IL 22, IL 23R and IL 1R1, and require RORα and RORγt as‐ ‐ ‐ ‐ ‐  
crucial transcription factors for their differentiation(Ghoreschi et al., 2010).
IL-17 is essential for host defence against many microbes, particularly 
extracellular bacteria and fungi, in particular for mucosal epithelia(O’Quinn et 
al.,  2008).  Interleukin-17  and  other  Th17  cytokines  are  linked  to  the 
pathogenesis  of  diverse  autoimmune  and  inflammatory  diseases.  The  IL-17 
receptor  is  expressed  ubiquitously,  and  hence  most  cells  can  potentially 
respond to this cytokine(Yao et al., 1997).
It has been noted that IL 17A expression can be induced within hours‐  
after infection or immunization with an adjuvant and before the differentiation 
of TH17 cells from native progenitors, which takes several days. This suggests 
that cells other than TH17 cells can produce IL 17. ‐
Mast cells also produce several members of the IL 17 family. Following‐  
Fcε receptor I mediated activation, mast cells produce substantial amounts of‐  
IL 17E, which can influence TH2 type responses‐ ‐ (Ikeda et al., 2003). Mast cells 
also  produce  IL 17A in  response  to  their  activation  by  Toll-like  receptor‐  
2(Mrabet-Dahbi  et  al.,  2009);  this  has  been  shown  in  several  diseases, 
including asthma, psoriasis(Lin et al., 2011), rheumatoid arthritis(Hueber et al., 
2010; Moran et al., 2011), and amyotrophic lateral sclerosis(Fiala et al., 2010). 
The  respective  contribution  of  IL 17  produced  by  these  different  cell‐  
types to disease pathology is still unknown. 
Interleukin-17 mediates adverse effects  in many autoimmune diseases. 
Before the discovery of the Th17 it was considered that Th1, Th2 and B cells 
were the main mediators of pathology in autoimmunity. 
Based on these observations, inhibitors — mostly monoclonal antibodies 
— have been designed, and the results of these clinical trials are now being 
released.
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder 
that  may  affect  many  tissues  and  organs,  but  principally  attacks  flexible 
(synovial) joints. It can be a disabling and painful condition, which can lead to 
substantial loss of functioning and mobility.
Inflammatory infiltrate of the joint synovium membrane leads to bone 
and cartilage destruction. The presence of IL 17 positive cells in the affected‐ ‐  
synovium and the production of functionally active IL 17 by this tissue was‐  
first demonstrated in this disorder(Lubberts et al., 2002).
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Interleukin-17 induces pro-inflammatory cytokines such as TNFα, IL-1β 
and IL-6 from cartilage, synoviocytes, macrophages and bone  cells(Shen and 
Gaffen, 2008). Collectively, these pro-inflammatory cytokines contribute to RA 
increase and also establish a chronic inflammatory state by a positive feedback 
loop wherein IL-17-induced IL-6 maintains the Th17 T-cell  population(Ogura 
et al., 2008). The IL-17 also stimulates the production of multiple chemokines, 
including IL-8/CXCL8, CXCL1, CXCL2, CCL20, CCL2 and CCL7(Fossiez et 
al., 1996; Park et al., 2005; Shen et al., 2005a; Shen and Gaffen, 2008). These 
serve to recruit neutrophils, macrophages and lymphocytes to the synovium, 
thereby enhancing inflammation. 
Inhibition  of  IL 17  with  antibodies  against  the  ligand  IL 17A or  its‐ ‐  
receptor  IL 17RA protected  against  the  development  and  consequences  of‐  
arthritis(Lubberts et al., 2004). Furthermore, mice lacking IL 17RA develop a‐  
very mild form of experimental arthritis.
Psoriasis 
Psoriasis is a chronic inflammatory skin disorder characterized by dermal 
hyperplasia.  The  key  histological  features  of  psoriatic  skin  are  epidermal 
keratinocyte  hyperproliferation,  vascular  proliferation  and  infiltration  of 
Dentritic Cells, macrophages, neutrophils and T cells(Nestle et al., 2009).
Psoriasis has been successfully treated using TNFα inhibitors in some but 
not all patients. Skin biopsy samples taken from patients with psoriasis showed 
high expression of IL 17 together with high expression of IL 23, IL 22 and IL‐ ‐ ‐ ‐
6(Zheng et al., 2007). Furthermore, increased numbers of TH1 and TH17 cells 
were found in blood and skin lesions of patients, showing a positive correlation 
with disease activity(Lowes et al., 2008). Local production of TH17 cytokines 
within  the  plaques  appears  to  contribute  to  the  increased  production  of 
chemokine CC motif ligand 20 (CCL20), a key chemokine that is necessary for 
the migration of TH17 cells(Harper et al., 2009). Mast cells and neutrophils 
represent additional sources of IL 17 in skin that is affected by psoriasis‐ (Lin et 
al., 2011). 
Multiple sclerosis 
Multiple sclerosis is a chronic inflammatory disease that leads to brain 
inflammation in which the myelin around the axons of the brain and spinal 
cord are damaged, leading to demyelination leading to a broad spectrum of 
signs and symptoms
Experimental  autoimmune  encephalomyelitis  (EAE)  is  a  model  of 
multiple sclerosis, a T-cell-mediated autoimmune disease of the central nervous 
system. It is elicited by immunization of neuroantigens, such as myelin basic 
protein and proteolipid protein. As with many other autoimmune conditions, 
Th1 cells were long thought to be responsible for EAE pathology, despite the 
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fact that IFN-/-, IFNcR-/- and IL-12p35-/- mice were susceptible(Ferber et al., 
1996; Becher et al., 2002; Zhang et al., 2003). Landmark studies comparing the 
IL-12p35-/- and IL-23p19-/- mice showed clearly that the Th17 path-way was 
responsible for pathology(Langrish et al., 2005).
Further evidence for the role of Th17 cells in driving EAE was shown in 
STAT6-/- / T-bet-/- doubly deficient mice, lacking Th1 and Th2 cells(Das et al., 
2009). IL-17 drive the tight  junctions distruption that  form the blood–brain 
barrier,  enabling Th17 cells  to  migrate  into the central  nervous system and 
cause  neuronal  damage(Kebir  et  al.,  2007).  Furthermore,  EAE in  the  mice 
could be ameliorated by treatment with anti-IL-17 antibodies. 
Asthma
Asthma is a common airway disorder that is  characterized by chronic 
airway inflammation, mucus production, and airway hyperresponsiveness with 
airway remodeling. 
Mouse models of asthma have yielded significant new insights recently. 
In  particular,  the  cytokine  IL-17E  (IL-25)  has  been  shown  to  have  a 
role(Tamachi et al., 2006).
IL-17E  was  proposed  to  initiate  and  maintain  Th2  responses. 
Furthermore,  by  directly  and/or  indirectly  inducing  the  expression  of,  in 
particular, IL-13 and IL-5, IL-17E may be responsible for the observed mucus 
production  and  lung  infiltration  of  eosinophils  during  allergic 
reactions(Claudio et al., 2009).
In asthmatic patients, IL-17 expression has been shown to increase in 
sputum,  lung  cells,  bronchoalveolar  lavage  fluids,  and  peripheral 
blood(Barczyk et al., 2003).
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Interleukin 17 Family
The IL-17 gene and IL 17 protein were first discovered as a product of T‐  
cells in rodents, but it was not immediately recognized as a cytokine, owing to 
its unusual amino acid sequence(Rouvier et al., 1993).
It is well established that IL 17 activity contributes to various aspects of‐  
acute  inflammation.  The  IL 17 mediated  release  of  IL 6  and  IL 8  from‐ ‐ ‐ ‐  
mesenchymal cells leads to fever, an acute phase response (caused by IL 6) and‐  
the accumulation of neutrophils in blood and tissue (caused by IL 8)‐ (Fossiez et 
al.,  1996).  IL 17 activity  also  contributes  to  chronic  inflammation‐ (Miossec, 
2003), which is often — but not always — associated with matrix destruction.
The IL 17 molecule is composed of two monomers that are linked by‐  
intramolecular  disulphide  bonds  on  cysteine  residues  to  form  a  homo  or 
eterodimer. IL 17 is now formally referred to as IL 17A in the literature and is‐ ‐  
the founding member of the IL 17 family, which is composed of six members‐  
— from IL 17A, IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25), and‐  
IL 17F‐ (Aggarwal and Gurney, 2002). 
IL 17A and  IL 17F  are  the  best  characterized  cytokines  of  the  IL 17‐ ‐ ‐  
cytokine family. Both are covalent homodimers, and recent findings show that 
they also form IL 17A–IL 17F heterodimers‐ ‐ (Chang and Dong, 2007).
IL 17A, IL 17F and the IL 17A–IL 17F heterodimer signal through the‐ ‐ ‐ ‐  
same receptor subunits: IL 17RA and IL 17RC‐ ‐ (Kuestner et al., 2007; Wright et 
al.,  2008).  Results  from mouse models,  comparing IL-17A-/-  and IL-17F-/- 
mice, indicate that some of the pro-inflammatory functions are not identical: 
IL 17A has a more important role in driving autoimmunity than IL 17F‐ ‐ (Yang 
et al., 2008). 
This  effect  is  probably  due  to  more  activity  of  IL-17A in  inducing 
inflammation: IL 17F induced responses are  10–30 fold weaker  in  terms of‐ ‐  
downstream  gene  activation  than  those  of  IL 17A,  with  IL 17A–IL 17F‐ ‐ ‐  
heterodimers acting at an intermediate level(McAllister et al., 2005).
In  contrast  to  the  other  members,  IL 17E  (IL 25)  induces  allergic‐ ‐  
responses and activation of the TH2 pathway and it is produced by mucosal 
epithelial cells and many immune cell types(Wang et al., 2007). Moreover, IL‐
17E inhibits Th17 cell development by inducing the expression of IL 13 by‐  
dendritic cells (DCs) or by inhibiting IL 23 ‐ production(Kleinschek et al., 2007; 
Dong, 2008a).
IL 17B, IL 17C and IL 17D functions are poorly defined .‐ ‐ ‐
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IL-17 Receptors
The first receptor to be identified for IL 17 was initially referred as IL 17‐ ‐  
receptor (IL 17R) but is now known as IL 17RA‐ ‐ (Yao et al., 1995). Afterwards 
additional receptor components, required to form a functional receptor complex 
for IL 17 signaling, were identify‐ (Yao et al., 1997). 
Four  additional  receptors  have  been  identified  in  the  IL 17R  family,‐  
based on sequence homology to IL 17RA: IL 17RB, IL 17RC, IL 17RD and‐ ‐ ‐ ‐  
IL 17RE, thus IL 17RA appears to be a common receptor chain for the IL 17‐ ‐ ‐  
family of ligands. 
All  receptor  subunits  are  single  transmembrane  domain containing‐  
proteins, these receptor subunits contain certain conserved structural motifs, 
including  an  extracellular  fibronectin  III like  domain  and  a  cytoplasmic‐  
domain named SEFIR, a member of STIR-domain superfamily. 
STIR-domain superfamily comprising TIR (Toll/Il-1 Receptor) domain, 
and SEFIR (SEF/IL 17R) domain. ‐
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Figure 2: IL-17R family ligand–receptor relationships and main structural 
features. Nat Rev Immunol. 2009 Aug;9(8):556-67.
TIR  domain  has  three  'boxes'  of  conserved  residues  and  a  important 
binding loop named BB-loop, SEFIR domain keep the same structure of TIR 
domain, but lack the TIR box 3 subdomain and the BB loop‐ (Novatchkova et 
al.,  2003).  However,  a  region  at  the  carboxy terminal  side  of  the  SEFIR‐  
domain in IL 17RA has marked sequence homology to BB loops. Deletion or‐ ‐  
point mutations in this region render IL 17RA non functional, so this motif is‐ ‐  
referred to as a TIR like loop (TILL)‐ (Maitra et al., 2007; Shen et al., 2009). 
Surprisingly, although all IL 17Rs have a SEFIR motif, the TILL domain‐  
seems to be unique to IL 17RA, perhaps explaining why IL 17RA functions as‐ ‐  
a common subunit shared by several receptors in the family. 
As mentioned IL 17RA is necessary for signal transduction mediated by‐  
IL 17A, IL 17A–IL 17F and IL 17F‐ ‐ ‐ ‐ (Hymowitz et al., 2001). Indeed, IL 17RA‐  
pairs  with  IL 17RC to  induce  responses  to  IL 17A and  IL 17F‐ ‐ ‐ (Toy  et  al., 
2006).  Similarly,  IL-17RA–/–  mice  are  refractory  to  the  effects  of  IL 17E,‐  
suggesting that IL 17RA is also a component of this receptor complex‐ (Rickel 
et al., 2008). 
IL 17RA is  expressed  ubiquitously,  with  particularly  high  levels  in‐  
haematopoietic  tissues(Yao  et  al.,  1995;  Ishigame et  al.,  2009),  but  only  a 
limited  number  of  IL 17A induced  genes  has  been  documented  in‐ ‐  
lymphocytes, and these genes are distinct from those induced by IL 17A in‐  
other cell types(Hsu et al., 2008; Ishigame et al., 2009), like endothelial cells 
and fibroblasts.
Another  function  of  IL 17RA seems  to  limit  signalling  by  receptor‐ ‐
mediated internalization of the ligand. Indeed, surface expression of IL 17RA‐  
rapidly decreases after IL 17A binding‐ (Lindemann et al., 2008). 
The precise stoichiometry of the IL 17A binding receptor complex has‐ ‐  
not been determined, but some data suggest the existence of a trimeric complex 
containing two IL 17RA subunits and one IL 17RC subunit‐ ‐ (You et al., 2006).
In contrast  to IL 17RA, IL 17RC expression is  low in haematopoietic‐ ‐  
tissues and high in non immune cells of the prostate, liver, kidney, thyroid and‐  
joints(Haudenschild  et  al.,  2002;  Kuestner  et  al.,  2007).  This  differential 
expression of IL 17R subunits is coerent with a mechanism for tissue specific‐ ‐  
signalling by IL 17A and/or IL 17F.‐ ‐
IL 17RB  instead  binds  both  IL 17B  and  IL 17E.  This  subunit  is‐ ‐ ‐  
expressed  by  various  endocrine  tissues  as  well  as  kidney,  liver  and  Th2 
cells(Lee et al., 2001). Recent evidence indicates that IL 17RB pairs with IL‐ ‐
17RA to form a functional receptor complex for IL 17E‐ (Rickel et al., 2008). 
IL 17RB is the one IL-17R that has a TRAF6 binding motif in its cytoplasmic‐ ‐  
tail(Maezawa et al., 2006). 
IL 17RD  and  IL-17RE  has  no  known  ligand  and  their  function  is‐  
14
unknown.
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IL-17: molecual pathway
IL-17 stimulation lead  to  two major  biological  responses:  1)  de novo 
transcription  and,  2)  stabilization  of  mRNA.  Both  biological  responses  are 
medieted by CIKS(Sun et al., 2011) (also known as ACT1 or TRAF3IP2) that 
is recruited to the receptor after IL-17 stimulation. Insteed genetic ablation of 
CIKS gene in mice, leads to unresponsiveness to IL-17 stimulation(Claudio et 
al., 2009).
CIKS contains a SEFIR domain, an E3 ubiquitin ligase domain(Liu et al., 
2009), and a binding site to TRAF6(Sønder et al., 2012). The binding between 
CIKS and IL-17RA is mediated by a SEFIR-SEFIR domains interaction.  In 
particular CIKS binds to the CC  loop region of the cytoplasmic tail of ILʹ ‐
17RA. 
After receptor binding CIKS recruits and ubiquitinates TRAF6 through 
K63 in a U-box – dependent manner(Liu et al., 2009). 
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This  signal  drive  TRAF6  to  the  activation  of  NF-κB  via  TAK-IKK 
complex(Deng  et  al.,  2000).  Like  the  activation  of  NF-κB  by  TLR,  IKK 
complex  induces  the  phosphorylation,  degradation  of  IκBα  and  subsequent 
activation of  NF-κB(Schwandner  et  al.,  2000;  Liu et  al.,  2009).  Some data 
demonstrate that NF-κB p65 and p50 subunits quickly associate with NF-κB 
response  element  upon  IL-17  stimulation(Ruddy  et  al.,  2004;  Shen  et  al., 
2006).  There  is  no  evidence  of  processing  of  other  noncanonical  NF-κB 
subunits.  Interestingly,  IL-17  also  induces  expression  of  IκBζ(Shen  et  al., 
2005a),  a  positive  regulator  of  NF-κB  activation(Yamamoto  et  al.,  2004). 
Recently, additional evidence suggests that IκBζ plays an important role in IL-
17–induced  expression  of  human  β-defensin  2  and  neutrophil  gelatinase-
associated lipocalin(Karlsen et al., 2010).
IL-17  signaling  also  activates  C/EBPs.  Among  all  C/EBP  family 
members, only C/EBP-  β and C/EBP-δ are transcriptionally up-regulated by 
IL-17(Shen et al.,  2005b).  The cooperation of NF-κB and C/EBPs can only 
partially explain the synergistic effect of IL-17 and TNFα. 
IL-17A also activates the MAPK pathway. Within 30 minutes of IL- 17A 
stimulation,  ERK  is  rapidly  phosphorylated  and  then  regulates  various 
downstream signaling components, including NF-κB, C/EBP, and AP1(Maitra 
et al., 2007).
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mRNA stability IL-17 dependent
Once mRNAs are transcribed they are subjected to post-transcriptional 
events  that  regulate  mRNA metabolism  including  stability  and  translation. 
These two processes normally dictate the protein levels encoded by mRNA. 
RNA-binding proteins that bind mature mRNA sequences normally  have an 
important regulatory effect on the mRNA.
One major effect of IL 17 is an increase in mRNA stability, this effect is‐  
evident when IL-17 is used in combination with other cytokines like TNFα. 
The IL-17 mediated mRNA stability has been demonstrated for different genes 
including G-CSF and CXCL1(Henness et al., 2004; Hartupee et al., 2007).
This  increas half-life  of  chemokine  mRNA is  mediated  by  an  CIKS-
dependent  but  TRAF6-independent  pathway(Hartupee  et  al.,  2007).  This 
observations  indicate  that  IL-17-mediated  stabilization  of  CXCL1  mRNA 
involves a distinct signal-transduction pathway(Hamilton et al., 2010).
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Figure 4: mRNA metabolism. From Abdelmohsen, K.in Binding Protein 
(Abdelmohsen, K.) (InTech, 2012)
Receptor triggering also promoted interaction between CIKS and TRAF2 
or  TRAF5,  and  IKKε (also  named  IKKi).  These  proteins  are  involved  for 
mRNA stabilization of Cxcl1(Bulek et al., 2011; Sun et al., 2011).
IKKε is able to phosphorylate CIKS on Ser 311, located adjacent to a 
putative TRAF-interacting consensus motif(Liu et  al.,  2009).  Computational 
modeling analysis suggest that phosphorylation of CIKS Ser 311 modulated its 
affinity for TRAF5/TRAF2.
IKKε deficiency and substitution of CIKS Ser 311 indeed abolished IL-
17-induced formation of the CIKS-TRAF2/TRAF5 complex and stabilization 
of  chemokine  mRNA,  whereas  the  CIKS–TRAF6–NF-κB  axis  was 
retained(Bulek et al., 2011).
The  complex  formed  by  CIKS,  IKKε  and  TRAFs induce  also  the 
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association  of  SF2  (also  named  ASF),  a  multifunctional  RNA-splicing 
regulatory  factor.  SF2  selectively  enhanced  the  decay  of  target  mRNA by 
binding to sites in 3′ UTRs. This interaction is disrupted by IL-17, perhaps via 
TRAF5-dependent  sequestration  of  limiting  amounts  of  cytoplasmic  SF2 
(ASF).(Sun et al., 2011)
Notably,  mRNA-decay  mechanisms  can  be  regulated  via  MAPK-
dependent signaling, including signaling by p38, Erk and Jnk(Rowlett et al., 
2008). 
Target genes IL-17 dependent
IL-17 downstream targets can be categorized into five major groups: 
1) chemokines;
2) proinflammatory cytokines and inflammatory mediator related genes; 
3) antimicrobial peptides; 
4) tissue remodeling genes; 
5) signaling components such as C/EBPβ , C/EBPδ , and IκBζ
CXCL1, CXCL2, and CXCL5 are the major mediators of the IL-17–induced 
neutrophil response in host defense and various inflammatory disease models. 
IL-17F alone or in combination with IFNγ can stimulate CXCL10 production 
in bronchial epithelial  cells(Kawaguchi et al., 2007). Other CXC chemokines 
such as CXCL6, CXCL8, and CXCL12 are also regulated by IL-17. CCL2 and 
CCL20 are among the few CC chemokines up-regulated by IL-17(Kao et al., 
2005). 
IL-17A  induces  production  of  other  proinflammatory  cytokines  in 
various cell types. For example, IL-6 is one of the earliest target genes reported 
in IL-17A–stimulated fibroblasts(Yao et al., 1995). G-CSF is another important 
cytokine that is induced by the IL-17 pathway. 
IL-17  (like  IL-1  and  TLR)  also  induce  a  anti-inflammatory  RNase: 
Zc3h12a (also know as MCPIP or MCPIP1) that selectively degrades specific 
target mRNA, like IL-1, IL-6 or IL-12, to modulates the immune response and 
inflammation(Huang  et  al.,  2012). Zc3h12a  recognizes  the  3'-untranslated 
region (UTR) of the mRNA, it is able to cleaved the mRNA and it is required 
for normal decay of mRNA. It triggers apoptosis and promotes angiogenesis in 
response to the binding of CCL2 to CCR2(Matsushita et al., 2009). Zc3h12 is 
20
also a Interferon Stimulated Genes (IGSs) induced by interferon-γ, and it has 
been hypothesized to suppress the antiviral state(Abe et al., 2011).
Antimicrobial peptides are important mediators of innate immunity; and 
IL-17A is  a  potent  inducer  of  various  antimicrobial  peptides.  Lipocalin  2 
(24p3) plays an important role in host defense against E. coli and Klebsiella 
pneumoniae by limiting bacterial siderophores to bind free  iron(Goetz et al., 
2002). In fibroblast cells, IL-17A alone or with TNFα results in quick induction 
of 24p3  protein(Shen et al., 2006). As another example, human β-defensin 2 
(hBD2) is  an antimicrobial  peptide and a  chemo-attractant  to  CCR6+ cells. 
hBD2 is markedly up-regulated by IL-17A in human airway epithelium and 
during virus infection(Kao et al., 2008).
IL-17A also  induces  expression  of  MMPs,  including  MMP1,  MMP2, 
MMP9,  and  MMP13,  which  are  the  major  players  in  extracellular  matrix 
degradation and bone resorption(Sylvester et al., 2004). Mice lacking IL-17RA 
fail  to  express  MMPs in  streptococcal  cell  wall  induced-arthritis  and show 
amelioration of cartilage destruction(Koenders et al., 2005).
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DEAD-box protein 3 - DDX3X
DEAD box proteins form the largest helicase family, with 37 members in 
humans(Fairman et al., 2004), and are characterized by the presence of an Asp‐
Glu Ala Asp (DEAD) motif. DEAD-box protein are involved in‐ ‐  all aspects of 
RNA  metabolism,  from  transcription  and  translation  to  mRNA 
decay(Jankowsky, 2011).
Although all DEAD box proteins contain a structurally highly conserved 
core with conserved ATP-binding and RNA-binding sites, different members of 
the  family  have  been  associated  with  diverse  and  seemingly  unrelated 
functions,  including  the  disassembly  of  RNPs,  chaperoning  during  RNA 
folding  and even  stabilization  of  protein  complexes  on  RNA(Cordin  et  al., 
2006; Jarmoskaite and Russell, 2011).
Members of the DEAD box family contain a highly conserved helicase 
core that harbours the binding sites for ATP and RNA(Caruthers and McKay, 
2002; Fairman et al., 2004; Singleton et al., 2007). The core is surrounded by 
variable  auxiliary domains,  which are  thought  to  be critical  for  the diverse 
functions of these enzymes. 
Within this helicase core, at least 12 characteristic sequence motifs are 
located at conserved positions. Some of these motifs are conserved across the 
entire  SF2  family,  whereas  others  are  found  only  in  the  DEAD  box 
family(Fairman et  al.,  2004). Motif II,  which contains the Asp-Glu-Ala-Asp 
motif, inspired the name DEAD box for this family(Linder et al., 1989).
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The two helicase domains form a cleft  that harbours the ATP-binding 
site, which is located between the two domains(Hilbert et al., 2009). Despite 
the high structural conservation of the helicase core, DEAD box proteins have 
been  associated  with  an  intriguing  array  of  cellular  functions,  from 
disassembling RNPs to serving as immobile RNA clamps(Tanner and Linder, 
2001;  Jankowsky,  2011).  Similarly  to  most  proteins  involved  in  RNA 
metabolism, DEAD box proteins usually function within complexes containing 
dozens  or  even  hundreds  of  components,  such  as  the  spliceosome  or  the 
nascent  ribosome.  In  addition  to  ATP-dependent  RNA  unwinding  and 
clamping,  DEAD box proteins  can remove proteins  from RNA in  an ATP- 
driven reaction(Kistler and Guthrie, 2001; Fairman et al., 2004).
DDX3X (also know as DBX or DDX3) was first identified in 1997(Park 
et  al.,  1998).  DDX3X  was  found  to  be  part  of  cytoplasmic  complexes 
containing eIF2, eIF3, eIF4A, eIF4E, and mRNA translation was affected by 
DDX3X  overexpression  or  DDX3X  knock  down(Geissler  et  al.,  2012). 
Furthermore DDX3X is able to bind 5' free extremity of the specific mRNA, 
and this is essential to starting the translation(Soto-Rifo et al., 2012). 
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Figure 6: Structure of the DEAD box helicase core. Nat Rev Mol Cell Biol. 
2011 Jul 22;12(8):505-16
DDX3X  interact  with  the  HBV  (hepatitis  B  virus)  protein  pol 
(polymerase). DDX3X was incorporated into nucleocapsids together with HBV 
pol and inhibited the initial step of reverse transcription in a manner that was 
dependent on the ATPase activity of DDX3(Wang et al., 2009). 
 This suggested an antiviral role of DDX3 in HBV infection; however, it 
remained unclear how DDX3X interfered with viral replication. Interestingly, it 
has  been  shown  that  DDX3X  levels  are  decreased  in  a  fraction  of  HBV-
induced hepatocellular carcinoma cases(Chang et al., 2006). It is possible that 
the  virus  down-regulates  DDX3X  levels  to  relieve  the  inhibitory  effect  of 
DDX3 on its own replication(Schröder, 2011). Some studies demonstrated that 
HBV pol disrupts the interaction between IKKε and DDX3X(Wang and Ryu, 
2010).  DDX3X  is  also  inibithed  by  VACV  (vaccinia  virus)  protein 
K7(Schröder, 2011).
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AIM OF THE STUDY
IL-17 plays a critical role in host defense against different pathogens in 
mucosal epithelium. IL-17 induces and sustains tissue inflammation and drives 
the  immune  responses,  mainly  by  two  different  mechanisms.  The  first  is 
transcription  dependent  and  involves  transcription  of  genes  controlling 
inflammation,  the  second  is  dependent  upon  the  stabilization  of  different 
mRNA induced by other inflammatory cytokines, such as TNFα. 
In  the  last  few  years  some  of  the  mechanisms  regulating  these  two 
functions  have  been  elucidated.  However,  much  remains  to  be  understood 
about this molecular pathway. Aim of this study is the identification of new 
proteins  involved in  the  IL-17 signaling,  in  order  to  unravel  the  molecular 
mechanism regulating  the  IL-17  dependent  inflammatory  responses,  and  to 
identify new potential target for therapeutic intervention. 
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MATERIAL AND METHODS
Reagents, cell lines, and constructs. 
Recombinant  IL-17 and TNF were from Peprotech,  and were used at 
(200ng/ml)  and  2000U/ml,  respectively.  Anti-M2  (Flag)  was  from  Sigma-
Aldrich. Anti DDX3X was produced in rabbit using a recombinant fragment 
spanning the amino acids 1-222 of mouse DDX3X as antigene. Anti-TRAF6, 
anti-TRAF2, anti-TRAF5, anti-IKKe were from Santa Cruz Biotechnology.
HEK293, wild type mouse embryonic fibroblast  (MEF),  CIKS-/- MEF, 
HeLa  were  maintained  in  Dulbecco  modified  Eagle  medium  (DMED) 
supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich), antibiotics 
(100  µg/mL penicillin,  100  µg/mL streptomycin),  and  1  mM  L-glutamine 
(Invitrogen). WT and CIKS-/- MEF were a gift of U. Siebenlist (NIAID, NIH).
The cDNA encoding CIKS and its  mutants were previously described 
(PNAS,  BBRC).  The  cDNA encoding  DDX3X  was  a  gift  of  Dr  Tilmann 
Bürckstümmer  (Haplogen  GmbH  ,  Wien,  Austria).  DDX3X  mutants  were 
generated by PCR and cloned in pCDNA3.1-HA or FLAG (Invitrogene).
RNA-interference (RNAi) and transfection.
Cells  were  transfected  with  small  interfering  RNA  oligonucleotides 
(20nM  final  concentration)  and  Interferin  (PolyPlus)  according  to 
manufacturer’s instruction. The siRNA sequence used are listed below:
Mouse DDX3X 5′-GAUGCUGGCUCGUGAUUUCU-3′
Mouse TRAF2 5′-CGACAUGAACAUCGCAAGC-3′
Mouse TRAF5 5'-AAGCCAGUGACCAGAGAUUAGUU-3'
To knock-down mouse IKK we used the esiRNA#EMU029351 (Sigma)
The  scrambled  control  was  from  Thermo  Scientific (siRNA  ON-
TARGETplus Non-targeting Pool #D-001810-10-05).
Seventytwo hours after transfection cells were collected for protein or 
RNA extraction. 
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Lentivirus production and infections.
FLAG-CIKS  cDNA  was  subcloned  into  pWPT  lentiviral  vector  at 
BamHI/SalI  sites.  The  construct  was  sequenced  to  confirm  correct  DNA 
sequence and orientation. Subconfluent 293T lentivirus packaging cells were 
cotransfected with either pWPT-GFP or Wip1-FLAG-pWPT and pMD2G and 
pCMV-R8.91  by  calcium  phosphate  precipitation.  After  24h  medium  was 
changed,  and  supernatant  was  harvested  after  48  and  72  hours.  Lentiviral 
supernatant, cleared of cell debris, was concentrated by centrifugation for 90 
min at 23000 rpm at 4°C. For transduction, CIKS-/- MEFs were plated on 12-
well  plate,  infected  with  lentiviruses  in  the  presence  of  10% foetal  bovine 
serum  and  8g/ml  polybrene  (Hexadimethrine  bromide;  Sigma-Aldrich, 
Milano, ITALY). 
Coimmunoprecipitation and immunoblot analysis.
CIKS-/- MEF reconstituted with FLAG-CIKS or with empty vector were 
left untreated or treated with IL-17 at different time points, were harvested by 
washing with ice-cold PBS, and then lysed with Lysis buffer (20 mM HEPES 
pH7.5, 150 mM NaCl,  1% Triton X-100, 10% Glycerol,  10mM NaF, 1mM 
Na3VO4)  freshly  supplemented  with  protease  inhibitors  cocktail  (Roche). 
Nuclear and cellular debris were removed by centrifugation at 14,000 x g for 
30 min at 4°C. Cell extracts were normalized for protein content, and incubated 
with 20 ml of M2 beads for 3 hours at 4°C. Beads were washed five times with 
Lysis buffer, and boiled in SDS sample buffer, and the resulting supernatants 
were subjected to 10% SDS/PAGE. 
For identification of the CIKS-interacting proteins, 100mg of cell extract 
from CIKS-/- and reconstituted MEF were incubated with 500 l of M2 beads 
(Sigma)  pre-washed with  Glycine  pH3.0  to  eliminate  not  covalently  bound 
antibody. After 3 hours incubation at 4°C, beads were washed four times with 
Lysis buffer, 2 times with High Salt  (1M NaCl) Lysis buffer.  Proteins were 
eluted from the beads by using 500l of 3xFLAG peptide (Sigma) 200mg/ml. 
Eluted  proteins  were  separated  by  SDS/PAGE  on a  9-16% T gradient  gel, 
which  was  then  stained  with  colloidal  Coomassie  G-250  (Candiano).  Gel 
image  was  acquired  by  using  an  Image  Scanner  III  densitometer  (GE 
Healthcare Life Sciences). Slices (15 in number) were excised from the lanes 
corresponding  to  the  bait  and  mock  samples  present  in  the  resolving  gel, 
triturated,  in-gel reduced, S-alkylated and digested with trypsin as previously 
reported (D’Ambrosio). 
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Peptide mixtures were desalted on home-made desalting tips (Empore C18 
extraction disk, 3M USA) and analyzed by nLC-ESI-LIT-MS/MS; a LTQ XL 
mass  spectrometer  (Thermo,San  Jose,  CA,  USA) equipped  with  a  Proxeon 
nanospray source connected to an Easy-nanoLC (Proxeon, Odense, Denmark) 
was used to  this  purpose.  Peptide  mixtures  were  separated  on  an  Easy C18 
column (100  x  0.075  mm,  3  m) (Proxeon)  by  using  a  linear  gradient  of 
acetonitrile  containing  0.1%  formic  acid  in  aqueous  0.1%  formic  acid; 
acetonitrile was ramped from 5% to 40%, over 40 min, and from 40% to 80% 
in 10 min, at flow rate of 300 nL/min. Spectra were acquired in the range m/z 
400–2000.  Acquisition  was  controlled  by  a  data-dependent  product  ion 
scanning  procedure  over  the  three  most  abundant  ions,  enabling  dynamic 
exclusion (repeat count 2 and exclusion duration 1 min). 
The mass isolation window and collision energy were set to  m/z 3 and 
35%, respectively. Two technical replicates were performed for each sample. 
Proteome Discoverer platform (Thermo, San Jose, CA, USA) was employed to 
search raw mass data against an updated Uniprot database of human sequences 
(2011/6) using both Sequest (Thermo, USA) and Mascot (Matrix Science, UK) 
algorithms.  nLC-ESI-LIT-MS/MS  data  were  searched  by  using  a  mass 
tolerance value of 2 Da for precursor ions and 0.8 Da for MS/MS fragments, 
trypsin as proteolytic enzyme, a missed-cleavage maximum value of 2,  and 
Cys  carbamidomethylation  and  Met  oxidation  as  fixed  and  variable 
modifications,  respectively.  Candidate  proteins  with  more  than  2  assigned 
peptides with an individual MASCOT score >25, or filtered by Sequest Xcorr 
(>1.8  for  +1,  >2.0  for  +2,  >2.2  for  +3  and  higher  charges),  and  with  a 
significant  threshold  p <  0.05,  were  further  considered  for  protein 
identification.  CIKS-interacting  proteins  were  identified  by  subtracting  the 
components ascertained within the bait with that ones from the corresponding 
mock.
Gel filtration of cellular extract.
Reconstituted  CIKS-/- MEF  were  lysed  in  Triton  X-100  lysis  buffer. 
Lysates were incubated for 15 min on ice and clarified by centrifugation at 
14,000 rpm for 15 min, 4 °C. Supernatants were collected and recentrifuged for 
1 h at 100,000xg at 4 °C. One milligram of the S-100 extracts (0.5 ml) was 
loaded onto a Superdex S200 HR (Amersham–Pharmacia Biotech).  Proteins 
were eluted from the column at the flow rate of 0.3 ml/min. Fractions (0.5 ml) 
were  precipitated  with  10% trichloroacetic  acid,  resuspended  in  Laemmli’s 
buffer,  and  analyzed  by  SDS–PAGE  followed  by  Western  blotting  using 
appropriate antibodies.
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RNA isolation and Real-Time PCR. 
Total  RNA  was  extracted  by  using  TRIZOL  reagent  according  to 
manufacturer’s  instruction  (Invitrogene).  Real-time RT-PCR was carried  out 
with cDNAs reverse-transcribed from total RNA by using GoTaq qPCR Master 
Mix (Promega, Madison, WI, USA) and Bio-Rad CFX Manager software (Bio-
Rad, Segrate, MI, ITALY). The primers used were:
GAPDH:  FW:  5'-ATGGTGAAGGTCGGTGTGAAC-3'  REV:  5'-
CCATGTAGTTGAGGTCAATGAAG-3'
Zc3h12a:  FW:  5'-AACTGGTTTCTGGAGCGAGG-3'  REV:  5'-
CGAAGGATGTGCTGGTCTGT-3'
Cxcl1:  FW:  5'-AGCCACCCGCTCGCTTCTCT-3'  REV:  5'-
GTCCCGAGCGAGACGAGACCA-3' 
IKK:  FW:  5'-CCACGTCTTTTCCCTACCCC-3'  REV:  5'-
GATGGCAATCGTGTTGTGGG-3'
DDX3X:  FW:  5'-GTAGAGGCAGCCTTTGCTCA-3'  REV:  5'-
ATAACGCCCTTTGCTTGCTG-3'
CXCL2: FW:  5'-CCCAGACAGAAGTCATAGCCA  -3'  REV:  5'-
CAGGTACGATCCAGGCTTCC -3'
CCL2: FW:  5'-AGCTGTAGTTTTTGTCACCAAGC-3'  REV:  5'-
GTGCTGAAGACCTTAGGGCA-3'
CXCL5: FW:  5'-AGAAGGAGGTCTGTCTGGATCCA-3'  REV:  5'-
CGAGTGCATTCCGCTTAGCTTTC-3'
IL6: FW:  5'-AAAGCCAGAGTCCTTCAGAGAGA-3'  REV:  5'-
GGTCCTTAGCCACTCCTTCTGTG-3'
LCN2: FW:  5'-ACAGAGCTACAATGTGCAAGTG-3'  REV:  5'-
CAGCTCCTTGGTTCTTCCATACA-3'
TRAF2:  FW:  5’-GCCTTTCCAGATAACGCTGC-3’  REV:  5’-
TCGTGGCAGCTCTCGTATTC-3’
TRAF5:  FW:  5’-CGCACCTGTCCCTGTACTTT-3’  REV  5’-
AGGCAATGTTCATCTCGCCA-3’
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RESULTS
Identification of DDX3X as a specific CIKS-interacting protein.
In order to clarify the molecular mechanism regulating IL-17 signaling 
we decided to isolate new CIKS interactors. 
We  set  up  an  experimental  system  constituted  by  MEF  (Mouse 
embryonic  fibroblast)  isolated  from  CIKS-/- mice,  and  the  same  cells 
reconstituted by lentiviral infection, with FLAG-CIKS. 
The  level  of  expression  of  FLAG-CIKS in  the  reconstituted  cells,  is 
comparable  to  the  endogenous  protein.  In  fact,  no  transcription  of  IL-17 
dependent genes is detected in unstimulated cells, while a strong transcriptional 
response is observed after IL-17 stimulation, comparable to that detected in wt 
MEF (Fig  7).  In  addition,  when the  cells  were  stimulated  with  IL-17 plus 
TNFα, there was a synergistic effect on mRNA levels. This effect was due to 
mRNA neo-synthesis  through TNFα  signaling,  and  to mRNA stabilization 
induced by IL-17. As shown in figure 7 treatment of wt and reconstituted MEF 
with IL-17 results in upregulation of different IL-17 target genes:  cxcl1 (B), 
ccl2 (C), cxcl5 (D), IL6 (E), Lcn2 (F). In the absence of CIKS both the IL-17 
dependent  transcription  and  the  IL-17  dependent  mRNA stabilization  were 
absent.
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To search for CIKS-interacting proteins, cell extracts from  CIKS-/- and 
reconstituted  MEF  were  immunoprecipated  and  analysed  by  mass 
31
Figure 7: Functional caracterization of WT, CIKS-/-, and reconstituted MEF. 
Cells were stimulated with TNFα, IL-17 or both cytokines for 6 hours, RNA 
extracted and the level of the indicated RNAs were assessed by Real Time PCR.
spectrometry.  I  found  about  30  interactors  immunoprecipitated  from  the 
reconstituted cells but not in the CIKS-/- cells, some of them are already known 
as CIKS interactors, such as IKKε and SF2. 
We decided to investigate one of this interactor: DDX3X to confirm this 
interaction.  DDX3X was  cloned  in  pcDNA3.1  and  transiently  trasfected  in 
HEK-293 cells.  As shown in figure 9 DDX3X was co-immunoprecipitating 
with FLAG-CIKS.
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Figure 8: Immunoprecipitation of FLAG-CIKS followed by mass spectrometry 
analysis. Cell lysate were immunoprecipitated with anti-FLAG Ab and eluted 
wit 3xFLAG peptide. The eluate is used to SDS-PAGE followed by silver stain. 
The gel was sliced and sended fot mass spectrometry analysis.
Domain mapping of the interaction between CIKS and DDX3X. 
To map the region of  CIKS necessary to  interact  with DDX3X some 
deletion mutants of CIKS were used. We used CIKS full length, CIKS 1-400 
lacking the SEFIR domain,  CIKS 101-574 lacking the first  100 aminoacids 
containing the TRAF6 binding site, and CIKS ΔUb that lose the Ubox domain. 
A schematic representation of these constructs is illustrated in figure 10B. We 
trasfected  these  constructs  in  HEK-293  together  with  DDX3X, 
immunoprecipitated CIKS and looked for DDX3X. As shown in figure 10A 
both the N- and the C-terminal of CIKS are essential for the interaction with 
DDX3X because by immunoprecipitating FLAG-CIKS, the HA-DDX3X bands 
was revealed only when both N- and C-term were present.
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Figure 9: CIKS interact with DDX3X. HEK 
293 were trasfected with expression plasmids  
for HA-tagged DDX3X and FLAG-tagged 
CIKS . The immunoprecipitates were 
analysed by Western blot with anti-HA 
(upper panel). Expression of CIKS and 
DDX3X was confirmed by western blot with 
anti-HA (middle panel) and anti-FLAG 
(lower panel) Abs, respectively. 
Next, we investigated the region of DDX3X involved in the binding to 
CIKS. The deletion mutants of  DDX3X are illustrated in figure 11B. Figure 
11A shown a  co-immunoprecipitation assay between FLAG-CIKS and HA-
tagged  DDX3X  full  length  or  bearing  different  mutations.  Deletion  of  the 
Gly/Ser-rich  domain  at  the  C-terminus  of  DDX3X  or  deletion  of  the  N-
terminus of DDX3X did not affect the binding of DDX3X with CIKS. Deletion 
of the helicase domain disrupted the binding, thus suggesting that helicase core 
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domain is involved in CIKS interaction.
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CIKS/DDX3X interaction is modulated by IL-17.
In  order  to  detect  the  interaction  between  CIKS  and  endogenous 
DDX3X, we generated an antibody. We cloned the portion 1-222 of DDX3X in 
a  bacterial  expression  vector,  purified  the  protein  by  Nickel  affinity 
chromatography and used it as antigen (Fig. 12A e B). Specifity of the antibody 
is illustrated in figure 12. We then investigated if the interaction between CIKS 
and DDX3X was dependent upon IL-17 stimulation. As shown in figure 13 
treatment  of  reconstituted  MEF with  IL-17 for  different  time enhanced the 
interaction with endogenous DDX3X.
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Figure 12: anti-DDX3X Ab production. A, SDS-PAGE with Blue Comassie 
stain loaded with molecular marker (M), total extract (Tot), and the seguent 
fraction by nikel resin purification: flow through (Fl. Tr.), wash pH8, elution 
pH 6,3, elution pH 5,9, elution pH 4,5. B, SDS-PAGE with western blot anti-
His. C, D, western blot with pre-immune serum and immune serum from rabbit  
inoculated with recombinant DDX3X respectively. E,F, purified Ab after 
affinity cromatography with His-DDX3X and the flow through.
To  further  confirm  the  DDX3X  was  involved  in  IL-17  signaling  we 
treated reconstituted MEF with IL-17, separated the cell extract by gel filtration 
chromatography  and analysed  the  fractions  by  Western  blot.  The figure  14 
shows that following IL-17 stimulation, endogenous DDX3X was eluted from 
the  column  in  the  same  fraction  containing  CIKS,  further  suggesting  the 
formation of complex between the two proteins after IL-17 stimulation.
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DDX3X control Zc3h12a mRNA half-life.
Because CIKS is essential for IL-17 mediated biological responses we 
sought to investigate if DDX3X was involved with some of the IL-17 mediated 
functions, such as gene expression and mRNA stability. 
No difference were observed by DDX3X over-expression in terms of NF- 
κB activation (Fig.15)
We knocked down DDX3X expression in MEF by using siRNA (fig. 16) 
and  in  these  cells  we evaluated  the  expression  of  different  IL-17-regulated 
genes.
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Figure 15: DDX3X is unable to activate NF-κB. Relative reporter activity was 
evaluated in HEK-293 cells co-transfected with the Ig-κB-luciferase plasmid and 
the indicated expression vectors.
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Next,  we  investigated  the  ability  of  DDX3X  to  mediate  the  IL-17-
induced stabilization of the some short-lived mRNA induced by TNFα. We 
treated CIKS-/-, reconstituted, and DDX3X KD MEF with TNFα for 60 minutes 
to induce transcription of target genes. Then we treated cells with Actinomycin 
D (to block de novo transcription) and IL-17 to induce mRNA stabilization. 
After 90 minutes cells were harvested, RNA extracted, and analyzed by Real 
Time PCR. As shown in figure 17 the half-life of zc3h12a was significantly 
decreased in DDX3X KD cells, compared to MEF treated with a scrambled 
siRNA. The ability of DDX3X to stabilize mRNA was selective for zc3h12a, 
as  the half  life of other  mRNA known to be stabilized by IL-17, including 
cxcl1, cxcl5, LCN2 and IL6 was not affected in the absence of DDX3X.
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Figure 16: sirna against DDX3X. A, western blot with MEF FLAG CIKS 
treated with siRNA scramble and siRNA DDX3X specific. B, real time analysis 
to evaluate the mRNA levels of MEF FLAG CIKS treated with siRNA scramble 
and siRNA DDX3X specific.
To further demonstrate that the half-life of zc3h12a mRNA depended on 
DDX3X  I  performed  a  time-course  with  IL-17/ActD  treatment,  and  the 
difference  between  zc3h12a mRNA levels  in  MEF FLAG CIKS and MEF 
siRNA DDX  was already significant after 60 minutes of treatment (Fig. 18). 
Cxcl1 was used as negative control (Fig. 18). In this experiment I used cxcl1 as 
negative control, because its mRNA level is CIKS-dependent, but not DDX3X-
dependent.
These  results  suggest  that  DDX3X is  involved  in  the  stabilization  of 
selected mRNA after IL-17 treatment. 
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Figure 17: DDX3X control zc3h12a mRNA half-life. zc3h12a, cxcl1, cxcl5,  
lcn2 and il6 mRNA levels in MEF FLAG CIKS, CIKS-/- MEF and MEF 
sirna DDX treated with TNFα for 1 hour and the same cells after IL-17 
and actinomycin D to block mRNA neo-syntesis. 
IKKε interacts with DDX3X and is required for mRNA 
stabilization
In order to gain insight into the mechanism used by DDX3X to stabilize 
zc3h12a, we investigated if IKKε, that has already been shown to be involved 
in this function was interacting with DDX3X. We transected HEK293 with the 
indicated expression vector (Fig 19),  immunoprecipitated Myc-tagged IKKε 
and looked for co-immunoprecipitating DDX3X. As shown in figure 19 IKKε 
was interacting with DDX3X, and this  interaction did not depend upon the 
presence of CIKS. Of note, in the presence of IKKε different form of DDX3X 
with apparent decreased relative mobility, appeared. The relative mobility of 
these forms of DDX3X were increased by treatment with phosphatase (data not 
shown), suggesting that DDX3X is phosphorylated by IKKε. 
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Figure 18: Zc3h12a mRNA is stabilized just then 60 minutes. Time 
corse of MEF FLAG CIKS and MEF sirna DDX3X treated with TNFα 
and IL-17/actinomycin D to induce mRNA stabilization and block the 
trascription. Cxcl1 was used such as control.
Next,  we  knocked  down  expression of  IKKε  in  MEF  (Fig.  20)  and 
evaluated the stability of zc3h12a mRNA. Cells were treated with TNFα for 60 
minutes, and then treated with Actinomycin D plus IL-17. As shown in figure 
20 the half life of  zc3h12a was significantly decreased in IKKε knock-down 
cells, compared to MEFs treated with a scrambled siRNA, thus suggesting that 
the IL-17-induced zc3h12a stabilization required IKKε.
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Figure 19:IKKε interact with DDX3X. HEK 293 were transfected with some 
expression plasmids for HA-tagged DDX3X, FLAG-tagged CIKS and MYC-
tagged IKKε. The immunoprecipitates with anti-IKKε Ab were analyzed by 
Western blot with anti-HA Ab (first panel). Expression of DDX3X, CIKS and 
IKKε was confirmed by western blot with anti-HA (second panel), anti-FLAG 
(third panel) and anti-Myc (fourth panel) Abs, respectively.
DDX3X is in TRAF6-independent pathway.
Next we investigated what domain of CIKS was necessary to stabilize 
zc3h12a. We reconstituted  CIKS-/- with  E17A, unable  to  bind  TRAF6.  The 
results  (Fig.  21) indicated that TRAF6 is not involved in this process since 
MEF CIKS E17A and MEF FLAG CIKS had the same zc3h12a mRNA level. 
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Figure 20: IKKε is necessary to zc3h12a mRNA stabilization. A, 
abundance of zc3h12a mRNA by Real Time PCR Analysis (normalized to 
that of GAPDH mRNA), presented as decay over time, of MEF FLAG 
CIKS, MEF si IKKε treated with TNFα/IL-17/ActD at different time. B, C, 
IKKε levels in MEF FLAG CIKS treated with siRNA screamble and sirna 
specific to IKKε by Real Time PCR analysis and western blot analysis 
respectively.
We investigated whether CIKS U-box domain was required for zc3h12a 
mRNA stabilization.  We  reconstituted  CIKS-/-  MEF  with  CIKS  ΔUbox,  a 
deletion mutant lacking the U-box domain. In figure 22 is shown that the U-
box was not required for zc3h12a mRNA stabilization. 
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Figure 21: Zc3h12a mRNA stabilization is TRAF6-indipendent. A, Western blot  
with cell lysate from CIKS-/- MEF and MEF reconstituted with FLAG-CIKS 
E17A with anti-FLAG Ab (upper panel) and anti-actin (lower panel). B, 
abundance of zc3h12a mRNA by Real Time PCR Analysis (normalized to that 
of GAPDH mRNA), presented as decay over time, of MEF FLAG CIKS, MEF 
CIKS E17A and MEF si DDX3X treated with TNFα/IL-17/ActD at different 
time.
TRAF2 and TRAF5 are required for Zc3h12a mRNA 
stabilization
TRAF2  and  TRAF5  are  two  proteins  involved  in  IL-17-dependent 
mRNA  stabilization.  To  study  the  involvement  of  these  two  proteins  in 
mediating the stabilization of zc3h12a induced by DDX3X, we down-regulated 
TRAF2  and  TRAF5  by  siRNA transfection,  and  evaluated  the  levels  of 
zc3h12a mRNA levels.  Figure 23 shows that both TRAF2 and TRAF5 was 
involved in  zc3h12a stabilization. In fact knocking down TRAF2 or TRAF5 
partially  affected  zc3h12a levels,  while  knocking  down  both  proteins  the 
zc3h12a stabilization was impaired (Fig. 23).
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Figure 22: CIKS U-box domain is dispensable for zc3h12a mRNA 
stabilization. Abundance of zc3h12a mRNA by Real Time PCR Analysis 
(normalized to that of GAPDH mRNA), presented as decay over time, of MEF 
FLAG CIKS, MEF CIKS dUbox and CIKS-/- MEF treated with TNFα/IL-
17/ActD at different time.
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Figure 23: TRAF2/5 are necessary for zc3h12a mRNA. A-D TRAF2 and 
TRAF5 levels in MEF FLAG CIKS treated with siRNA screamble and sirna 
specific to TRAF2/5 by Real Time PCR analysis and western blot analysis. E-
G, abundance of zc3h12a mRNA by Real Time PCR Analysis (normalized to 
that of GAPDH mRNA), presented as decay over time, of MEF FLAG CIKS, 
MEF siRNA TRAF2 alone, sirna TRAF5 alone or both, treated with TNFα/IL-
17/ActD at different time.
DDX3X bind directly Zc3h12a mRNA
To  demonstrate  whether  DDX3X  binds  directly  zc3h12a mRNA,  we 
ectopically expressed DDX3X in HeLa cells. Cells were treated with TNF plus 
IL17, cells were lysed, DDX3X was immunoprecipitated by using anti-FLAG 
antibody, and the presence of the  zc3h12a  mRNA in the  immunoprecipitate 
was detected by PCR. As shown in figure 24 it was possible to amplify the 
zc3h12a mRNA in the DDX3X immunoprecipitate after IL17 stimulation. thus 
proving that DDX3X is directly binding zc3h12a after IL-17 stimulation.
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DISCUSSION
In the present manuscript we present evidence that the helicase family 
member DDX3X is part of the mechanism regulating mRNA stability induced 
by IL-17. We demonstrate that DDX3X is interacting with CIKS, an essential 
component  of  the  IL-17  signaling  pathway,  and  that  this  interaction  is 
dependent  upon  IL-17  stimulation.  The  functional  consequence  of  this 
interaction is the stabilization of selected mRNA. In fact, DDX3X selectively 
enhance the half life of  zc3h12a mRNA by directly binding the mRNA in an 
IL-17-dependent manner, possibly protecting it from degradation. The DEAD-
box  RNA helicase  DDX3X  is  a  multifunctional  protein,  which  has  been 
implicated in different cellular processes linked to RNA metabolism and gene 
expression. Despite its involvement in almost every step of mRNA metabolism, 
this is the first evidence linking DDX3X to the stabilization of selected mRNA 
following  IL-17  stimulation.  DDX3X  has  also  been  demonstrated  to  be 
required for translation of selected mRNA, by directly binding the 5’ end of 
such  RNAs  and  facilitating  the  recruitment  of  eIF4F  complex  to  start 
translation.  It  is  then  possible  that  binding  of  DDX3X  to  the  zc3h12a is 
important  to  modulate  both  the  stability  of  the  zc3h12a mRNA and  its 
translation. How DDX3X is increasing the half life of zc3h12a is not currently 
clear. The simplest explanation is that after receptor triggering DDX3X binds 
the mRNA displacing other factors controlling the mRNA decay, and recruits 
the translational machinery to start translation. 
DDX3X has  also  been involved in  viral  sensing  pathway  at  different 
levels:  by enhancing the IPS-1 function;  by recruiting TBK1 and IKKε; by 
directly binding the IFN-β promoter, and by directly binding viral RNA. These 
results  suggest  that  DDX3X may be an important  component  of  the innate 
immunity, and that it may use the adaptor protein CIKS to signal the interferon 
response. However, at least in our experimental system, we have not been able 
to  detect  an  interaction  between  CIKS  and  DDX3X after  stimulation  with 
substances  mimicking  viral  nucleic  acids  such  as  poly(A:T),  poly(C:G), 
poly(I:C). In addition, we have not detected a statistically significant variation 
in  IFN-β production  (measured  by ELISA),  and IRF3/7 phosphorylation  in 
CIKS -/- MEF treated with poly(A:T), poly(C:G), poly(I:C). It is possible that 
DDX3X  may  function  in  various  signaling  pathways  regulating  different 
immune responses, such as mRNA stability in the IL-17 pathway, and type I 
interferon production in the innate immune system.
We  demonstrated  that  the  DDX3X-mediated  stabilization  of  zc3h12a 
mRNA requires IKKε, TRAF2 and TRAF5. This finding was not unexpected 
given that the stabilization of other  mRNA, such as  CXCL1,  has also been 
demonstrated to be mediated by TRAF2, TRAF5 and IKKε. Notably, TRAF2 
and TRAF5 seems to provide redundant functions in the IL-17 pathway, as 
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mRNA stability was completely abrogated only in double deficient cells. The 
functional  redundancy of TRAF2 and TRAF5 is  not  restricted to  the IL-17 
pathway, as also in other signaling pathways, such as TNF, the two proteins 
may compensate for the absence of the other.  Indeed, the phenotype of the 
TRAF2/TRAF5 double KO mice is way more complex that the phenotype of 
the single KO. However, in our experimental system, TRAF2 knock-down was 
more effective in blocking the IL-17 mediated stabilization of zc3h12a, which 
suggests  that  TRAF2 is  the  more  physiological  regulator.  It  remains  to  be 
determined if after IL-17 stimulation DDX3X forms a complex with TRAF2 
and TRAF5. This hypothesis is currently under investigation.
We also present evidence that a complex composed of CIKS, IKKε and 
DDX3X is formed after receptor triggering. Notably, in the presence of IKKε, 
DDX3X seems to be phosphorylated by IKKε, suggesting that this effect may 
be important to regulate DDX3X function. It has been recently reported that 
IKKε phosphorylates  DDX3X and  that  this  phosphorylation  modulated  the 
interaction between DDX3X and IRF3. It  is  possible that also in the IL-17 
pathway the phosphorylation of DDX3X affects DDX3X function, or its ability 
to interact with CIKS. However, we did not detect difference in the amount of 
CIKS immunoprecipitating with DDX3X in the presence or in the absence of 
IKKe.  We are  currently  investigating  if  the  ability  of  DDX3X to  bind  the 
zc3h12a is  affected  by  IKKε.  It  has  been  demonstrated  that  IKKε 
phosphorylates CIKS and that this event is required for the formation of the 
CIKS-TRAF2-TRAF5 complex mediating mRNA stability, while the formation 
of the CIKS-TRAF6 complex, regulating activation of NF-κB, is not affected. 
Our data confirm and expand this observation, as also the DDX3X mediated 
mRNA stabilization,  relies  on a  similar  mechanism,  independent  on NF-κB 
activation. In fact, in CIKS-/- MEF reconstituted with the CIKS mutant E17A 
unable to bind TRAF6 and to activate NF-κB, the DDX3X mediated mRNA 
stabilization is not affected. Similarly, also in CIKS-/- MEF reconstituted with a 
CIKS mutant lacking the Ubox domain (unable to activate NF-κB), the mRNA 
stability  is  retained.  It  is  then  possible  to  speculate  that  the  CIKS-TRAF2-
TRAF5  axis  activates  different  effector  mechanisms,  each  regulating  the 
stability of selected mRNA.
In summary,  we have  identified  a  previously  not  reported  association 
between CIKS and DDX3X, and we provide evidence that DDX3X mediates 
the stability of selected mRNA induced by IL-17. . 
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NGAL Controls the Metastatic Potential of Anaplastic
Thyroid Carcinoma Cells
Vincenzo Volpe, Zelinda Raia, Luca Sanguigno, Domenico Somma,
Paola Mastrovito, Fortunato Moscato, Stefano Mellone, Antonio Leonardi,
and Francesco Pacifico
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Consiglio Nazionale delle Ricerche, 80131 Naples, Italy
Context: We have previously identified neutrophil gelatinase-associated lipocalin (NGAL) as one
of the genes mediating the oncogenic activity of nuclear factor-B in human anaplastic thyroid
carcinomas (ATCs).
Objectives: To further investigate the role of NGAL in thyroid cancer, we established NGAL
knocked-down and NGAL overexpressing ATC cell lines.
Results:We found that the ability of NGAL knocked-down cells to degradeMatrigel in a transwell
invasionassay and to form lungmetastasis innudemicewasdecreased. BecauseNGALbindsmatrix
metalloproteinase-9 (MMP-9), to form a macromolecular complex involved in the regulation of
metastatic spread of cancer cells and given the strong expression of both genes in tissue specimens
from human ATCs, we analyzed the MMP-9 enzymatic activity in NGAL-null ATC cells. Enzymatic
immunoassays show that MMP-9 activity is reduced in NGAL-null ATC cells, even if its expression
is not affected by NGAL inhibition. Ectopic expression of NGAL in an ATC cell line not expressing
NGALdeterminesan increaseof itsmetastaticproperty. Theuseofamutated formofNGAL,unable
to bind MMP-9, has no positive effect on the invasive potential of ATC cells and does not improve
the MMP-9 enzymatic activity.
Conclusions:Our results indicateNGALas a novel target of nuclear factor-Bprometastatic activity
in thyroid cancer through enhancement ofMMP-9 enzymatic activity. (J Clin EndocrinolMetab 98:
0000–0000, 2013)
One of the most problematic aspects of cancer is rep-resented by metastatic disease that is largely incur-
able because of its systemic nature and the increased re-
sistance of metastatic cells to chemo- or radiotherapy. In
the vastmajority of cases, themortality from cancer is due
to metastases, not to the primary tumor (1, 2). Therefore,
a great effort has been attempting to understand the mo-
lecular mechanisms underlying the metastatic process to
identify novel targets for more effective therapeutic inter-
vention. Metastasis development is a very complex pro-
cess which requires a number of coordinated steps to suc-
cessfullypromote theonsetof secondaryneoplastic lesions
at organs distant from primary tumor. The initial event of
metastatic cascade is represented by local invasion of pri-
mary tumor cells to adjacent tissues. This process is
achieved by cancer cells via degradation of basement
membrane, a specialized extracellular matrix that plays
vital roles in organizing epithelial tissues. The degradation
of basement membrane occurs by proteolysis of extracel-
lular matrix components mediated by the activity of a
family of zinc and calcium dependent endopeptidases col-
lectively termed matrix metalloproteinases (MMPs) (3).
One of themost importantmetalloproteinases involved in
the invasion process isMMP-9, a 92-kDa protease able to
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degrade a broad range of substrates including collagens,
fibronectins, and laminins (4).MMP-9 is highly expressed
inmany human tumors, especially ofmore aggressive phe-
notype, and its levels generally correlate with a poor prog-
nosis (5–8). Its enzymatic activity is, at least partially,
regulated by neutrophil gelatinase-associated lipocalin
(NGAL), via the formation of a macromolecular complex
that allowsMMP-9 to preserve its proteolytic activity (9).
We have previously demonstrated that nuclear fac-
tor-B (NF-B) is strongly activated in human thyroid
cancer in which it plays an important role, given that the
inhibition of its activity in anaplastic thyroid carcinoma
(ATC) cells blocks their oncogenic potential (10). In the
effort to identify target genes of NF-B activity in thyroid
cancer, we found that NGAL is able to recapitulate some
of protumorigenic functions of NF-B in these tumors,
such as the ability to protect ATC cells from growth fac-
tors deprivation-induced apoptosis (11). NGAL, also
known as lipocalin-2, is a member of the large family of
lipocalins, a group of small extracellular proteins with
great functional diversity (12). It is overexpressed in a
numberofhuman tumors, includingbreast (13), lung (14),
colon (15), ovary (16), andpancreas (17) carcinomas. Sev-
eral studieshavedemonstrated thatNGALhasprotumori-
genic activity that occurs through the enhancementof neo-
plastic cell survival and proliferation, very likely due to its
iron-carrier function. In addition, NGAL contributes to
cancer by promoting the metastatic potential of tumor
cells because of its ability to protect MMP-9 from auto-
degradation (9, 18).
We found a strong coexpression of both NGAL and
MMP-9 in tissue specimens fromprimary humanATCs so
thatwedecided to investigate the roleofNGALin theATC
metastatic process by modulating its expression in two
ATC cell lines, BHT101 and Act1.
Materials and Methods
Cell culture and biological reagents
BHT101andAct1 cellswere kindly provided byProfessorM.
Santoro, “Federico II” University of Naples. To knock down
NGAL expression, BHT101 cells were infected with pLL 3.7
lentiviral vector containing double-strandedoligonucleotides se-
quences derived from the human NGAL in forward and reverse
orientation, separated by a 7-bp spacer region (caagaga) to allow
the formation of the hairpin structure in the expressed small
interfering RNAs (siRNAs): NGAL sc-siRNA, sense strand, 5-
CCATCTATGAGCTGAAAGAcaagagaTCTTTCAGCTCATA
GATGG-3, antisense strand, 5-CCATCTATGAGCTGAAAG
AtctcttgTCTTTCAGCTCATAGATGG-3; NGAL siRNA1,
sense strand, 5-GGGAATGCAATTCTCAGAGTTcaagagaAA
CTCTGAGAATTGCATTCCC-3, antisense strand, 5-GGGA
ATGCAATTCTCAGAGTTtctcttgAACTCTGAGAATTGCAT
TCCC-3; NGAL siRNA2, sense strand, 5-GGACTTTTGTT
CCAGGTTGTTcaagagaAACAACCTGGAACAAAAGTCC-3,
antisense strand, 5-GGACTTTTGTTCCAGGTTGTTtctcttgAA
CAACCTGGAACAAAAGTCC-3. Act1 cells were infected with
pLENTI CMV GFP-2A-PURO vector (ABM, Richmond, British
Columbia, Canada) alone or containing the cDNA coding for hu-
man wild-type or mutated NGAL fused in frame with the hemag-
glutinin (HA) tag. All cell lines were grown in DMEM (Sigma, St.
Louis, MO) supplemented with 10% fetal bovine serum (Sigma).
Anti-HA (sc-805 and sc-7392) and antiactin (sc-8432) were pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA),
anti-FLAG (F7425 and F3165) was from Sigma, and anti-NGAL
(AF1757) was from R&D Systems (Minneapolis, MN).
Patients
The study has been approved by the local ethics committees.
Informed consent of the patients had been obtained before their
inclusion in the study. Five cases of surgically resected ATCs and
two specimens of the normal controlateral thyroid lobe from
surgically resectedbenignadenomaswere analyzed for their abil-
ity to express NGAL and MMP-9 mRNAs. The clinicopatho-
logical characteristics of the ATC selected cases are shown in
Supplemental Table 1, published on The Endocrine Society’s
Journals Online web site at http://endo.endojournals.org.
mRNA quantification by real-time RT-PCR
Real-time RT-PCR was carried out with cDNAs reverse tran-
scribed from total RNA by using GoTaq qPCR master mix
(Promega, Madison, WI) and Bio-Rad CFX Manager software
(Bio-Rad Laboratories, Segrate, Milan, Italy), according to manu-
facturers’ procedure. The primers used were: glyceraldehyde-3-
phosphatedehydrogenase,forward,5-AAACAGAAGGCAGCTT
TACGATG-3, reverse,5-AAATGTTCTGATCCAGTAGCG-3;
NGAL, forward, 5-GAAGACAAAGACCCGCAAAAG-3, re-
verse, 5-CTGGCAACCTGGAACAAAAG-3; and MMP-9, for-
ward, 5-CGAACTTTGACAGCGACAAG-3, reverse, 5-CACT
GAGGAA TGATCTAAGCCC-3.
Immunoprecipitation and Western blots
For immunoprecipitation of transfected proteins, human em-
bryonic kidney (HEK) 293 cells (3 106) were transiently trans-
fected by using Lipofectamine 2000 reagent (Invitrogen, Carls-
bad, CA), and 24 h after transfection, cells were lysed in Triton
X-100 lysis buffer (20 mMHEPES, pH 7.4; 150 mMNaCl; 10%
glycerol; 1% Triton X-100; and Complete protease inhibitor
mixture). After an additional 15 min on ice, cell extracts were
centrifuged for 10 min at 14,000  g at 4 C, and supernatants
were incubated for 4 h at 4 C with anti-HA antibodies bound to
agarose beads (Sigma). The immunoprecipitates were washed
five times with Triton X-100 lysis buffer and subjected to
SDS-PAGE.
For Western blots, 20 g of total proteins from cell lysates
or supernatants was analyzed by 10% SDS-PAGE and blotted
onto nitrocellulose membrane (Schleicher & Schuell, What-
manGmbH,Dassel, Germany). Filters were blocked for 1 h 30
min at room temperature with 5% nonfat dry milk in TBST
buffer [10 mM Tris-HCl (pH 8), 0.1% Tween 20, 150 mM
NaCl] and incubated with 1:2000 dilution of anti-HA, anti-
FLAG, anti-NGAL, or antiactin antibodies for 1 h 30 min.
After TBST washing, blots were incubated for 1 h with horse-
radish peroxidase-conjugated secondary antibodies (NXA931;
AmershamBiosciences,Buckinghamshire,UK)diluted1:5000 in
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TBST buffer and then revealed by enhanced chemiluminescence
(Amersham Biosciences).
Matrigel invasion assays
Cell invasion was examined using a reconstituted extracellu-
lar matrix (Matrigel; BD Biosciences, Bedford, MA). Polycar-
bonatemembranes (8mmpore size) on the bottoms of the upper
compartment of the transwells (6.5 mm; Costar, Cambridge,
MA) were coated with 1.2 mg/ml Matrigel. The 1 105 cells in
100 l of serum-free Opti-MEM I (Invitrogen), alone or added
with recombinant NGAL (11), were placed on the Matrigel-
coated polycarbonate membrane in the upper compartment,
whereas 600 l of Opti-MEM I supplemented with 10% fetal
bovine serum was added to the lower compartment. The plates
were incubated at 37 C in a 5%CO2 atmosphere saturated with
H2O for 24 h. At the end of incubation, the cells andMatrigel at
the upper side of the polycarbonate filter were mechanically re-
moved. Cells that had invaded the Matrigel and migrated to the
lower side of the filter were fixed with 11% glutheraldeyde for
15 min at room temperature, washed three times with PBS, and
stained with 0.1% crystal violet-20% methanol for 20 min at
room temperature. After three PBS washes and complete drying
at room temperature, the crystal violet was solubilized by im-
merging the filters in 300 l of 10% acetic acid. The concentra-
tion of the solubilized crystal violet was evaluated as absorbance
at 590 nm. Experiments were performed at least in triplicate.
Results are SD of at least three separate experiments.
In vivo experiments
To analyze in vivo the metastatic activity of neoplastic cells,
1 107 cells were resuspended in 200l of PBS and injected into
the tail vein of 6-wk-old athymic mice divided into four groups
of six animals each one. Groups were injected as follows: group
1, PBS alone; group 2, BHT cells; group 3, BHT pLL sc-siRNA
cells; and group4, BHTpLL siRNA2. Fourweeks after injection,
mice were killed and lung metastasis was analyzed by standard
hematoxylin and eosin staining.
Analysis of MMP-9 activity
The quantitative determination of human active MMP-9 in
conditioned media from NGAL-proficient and -deficient
BHT101 and Act1 cell lines was performed by Fluorokine E
immunoassay, according to the manufacturer’s instructions
(R&DSystems). The relative fluorescence unitswere determined
with the PerkinElmer LS50B luminescence spectrometer (New
York, NY) using an excitation wavelength of 320 nm and an
emissionwavelength of 405 nm. Experimentswere performed at
least in triplicate. Results are SD of at least three separate
experiments.
Statistics
Datawere analyzedwith ANOVA and a Student’s t test anal-
ysis. Data are presented as the means  SD. P  0.05 was con-
sidered significant.
Results
MMP-9 and NGAL are overexpressed in human
ATCs
We have previously shown (11) that NGAL is strongly
expressed in human thyroid carcinomas, especially that of
the anaplastic type. Because it is known that in many tu-
morsNGAL expression parallels that ofMMP-9 (19–21),
we verified whether both genes were overexpressed in hu-
man thyroid tumors from the same tissue specimen. As
shown in Fig. 1A,MMP-9 expression is clearly more pro-
nounced in human ATCs than in normal thyroid tissues,
as assessed by quantitative RT-PCR (qRT-PCR) analysis,
and, importantly, it overlaps that of NGAL in the same
tissues (Fig. 1B), indicating that both genes are highly ex-
pressed in the most aggressive and metastatic types of hu-
man thyroid carcinomas.
Establishment of knocked-down and
overexpressing NGAL anaplastic thyroid carcinoma
cell lines
To study the role of NGAL in the metastatic activity of
ATC cells, we modulated its expression in two ATC cell
lines, BHT101 and Act1, that show different levels of
NGAL expression. BHT101 cells express high levels of
NGAL and secrete the protein in the culture medium,
whereas Act1 cells do not express NGAL that is not de-
tectable either in the whole cell extract or in the culture
medium (Fig. 2, A and B). Therefore, we knocked down
NGAL in BHT101 cells by infecting cells with two differ-
ent lentiviruses containing siRNAsequences that bind two
different regions of NGAL mRNA (pLL siRNA1 and -2).
In parallel, we ectopically expressed NGAL in Act1 cells
by infecting cells with a lentivirus carrying the cDNA en-
FIG. 1. MMP-9 and NGAL expression in primary human ATC
specimens. qRT-PCR of MMP-9 (A) and NGAL (B) in normal thyroid
(NT1 and NT2) and ATCs (ATC1, ATC2, ATC3, ATC7, and ATC8) from
human specimens. The relative amount of MMP-9 and NGAL mRNA
was normalized to the glyceraldehyde-3-phosphate dehydrogenase
mRNA. *, P  0.001; **, P  0.0001; ***, P  0.00001; ****, P 
0.000001.
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coding for humanNGAL.BHT101cells infectedwithpLL
siRNA1 and pLL siRNA2 showed a strong decrease of
NGAL expression compared with uninfected cells and to
control scrambled siRNA (Fig. 2A). The ectopic expres-
sion ofNGAL inAct1 cells was successfully achieved both
in lysates and extracellular media, as shown in Fig. 2B.
In addition, we also infected Act1 cells with a mutated
formofNGAL (C87R), carrying a substitution of cysteine
residue in position 87 with an arginine residue (C87R)
(Fig. 2B). This mutation impairs the ability of NGAL to
form thedisulfide bridgewithMMP-9, thereby interfering
with NGAL-mediatedMMP-9 protection from auto-deg-
radation and preventing association of tissue inhibitor of
metalloproteinase-1 with MMP-9 N-terminal domain
(22). To test the effectiveness of this substitution, we tran-
siently cotransfected HEK293 cells with FLAG-MMP-9
andNGAL-HAorwithFLAG-MMP-9andNGALC87R-
HA, respectively, and we coimmunoprecipitated them
with anti-HA antibodies. Western blot analysis of immu-
noprecipitated proteins with anti-FLAG antibodies re-
vealed that only wild-type NGAL-HA was able to bind
FLAG-MMP-9, whereas the mutated NGAL C87R-HA
was completely unable to interact with the metalloprotei-
nase (Fig. 3).
NGAL enhances the invasiveness of BHT101 and
Act1 cells
BothNGALknocked-downandNGALoverexpressing
cell lineswere tested for their ability to degradematrigel in
a transwell invasion assays. As shown in Fig. 4, all BHT
cell lines migrated through the transwell at similar extent,
independently of the presence of NGAL in the culture me-
dium (Fig. 4, A–C, left panels). However, they not de-
gradedmatrigelwith the sameefficiency (Fig. 4,A–C, right
panels). In particular, knocking down NGAL expression
determined the decrease of BHT cells invasiveness com-
pared with that of parental and sc-siRNA BHT cells, as
FIG. 3. The substitution of cysteine residue in position 87 with
arginine (C87R) impairs NGAL binding to MMP-9. HEK293 cells were
transfected with constructs encoding MMP-9, wild-type (WT), and
mutated (C87R) NGAL. Cell lysates were immunoprecipitated (IP) with
anti-HA antibodies (NGAL) and Western blotted (WB) with anti-FLAG
to reveal the coprecipitation of MMP-9 and NGAL. The presence of HA
and FLAG proteins in total lysates is shown in lower panels.
FIG. 2. Modulation of NGAL expression in ATC cell lines. Western blot of NGAL on conditioned media and lysates from BHT101 cells uninfected
and infected with pLL 3.7 NGAL siRNA1, siRNA2, or scrambled (sc) siRNA (A) and from Act1 cells uninfected and infected with pLENTI alone,
pLENTI NGAL-HA, or pLENTI NGAL C87R-HA (B). The expression levels of NGAL protein from lysates were normalized on actin content (A and B,
bottom panels), whereas those of conditioned media were normalized on total protein content determined by a Bradford assay (Bio-Rad
Laboratories).
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assessed by the reducednumber of bothBHTpLL siRNA1
and siRNA2 cells that degraded matrigel (Fig. 4D). The
addition of NGAL-containing conditioned medium or re-
combinant NGAL to the upper chamber of transwells re-
stored the invading activity of BHT pLL siRNA1 and
siRNA2 cells (Fig. 4, B–D). On the other hand, the ectopic
expression of NGAL in Act1 cells induced an increase of
their invasiveness, as assessed by amore pronounced abil-
ity of NGAL-expressing Act1 cells to degrade matrigel
compared with the parental and control vector cells (Fig.
FIG. 4. In vitro invasive properties of NGAL-proficient and -deficient ATC cell lines. Parental and infected BHT101 (A–C) and Act1 (E) cell lines
were used to analyze their ability to degrade Matrigel (BD Biosciences) in transwell assays. The extent of invasive potential was measured as the
number of Matrigel degrading cells on total migrating cells (D, *, P  0.01, **, P  0.001; and F, *, P  0.001). SFM, Serum-free medium; CM,
conditioned medium; rNGAL, recombinant NGAL.
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4, E and F). Importantly, Act1 cells expressing the C87R
NGAL mutant reversed the proinvading effects of wild-
typeNGAL, suggesting that interferingwith the formation
of NGAL/MMP9 complex is important in regulating the
prometastatic activity of MMP-9.
To confirm these results in vivo, we
injected parental and NGAL knocked-
down BHT101 cells in the tail vein of
athymic mice, which represents a pref-
erential way of access for tumor cells
migration to future metastatic sites, i.e.
lung and liver. Figure 5 shows the he-
matoxylin-and-eosin staining of lung
metastases from mice injected with un-
infected BHT101, BHT pLL sc-siRNA,
and BHT pLL siRNA2 cells. All three
cell lines gave rise to lung metastases
but at different extent. Inparticular, the
number of lung metastases from
BHT101NGAL-null cells injectedmice
were lower than those originated from
parental and scrambled BHT101 cells
(Fig. 5, A and B).
These results suggest that the pres-
ence of functional NGAL increased
the metastatic potential of ATC cells,
in vitro and in vivo, very likely thr-
ough the improvement of MMP-9
activity.
MMP-9 enzymatic activity is enhanced by the
presence of NGAL
To test our hypothesis, we evaluated the MMP-9 ac-
tivity in the parental and infected BHT101 and Act1 cell
lines by an immunoenzymatic assay. To this purpose, cells
FIG. 5. In vivo analysis of metastatic activity of NGAL-proficient and -deficient ATC cells.
Parental and infected BHT101 cells were injected in athymic mice tail vein to analyze their
ability to form lung metastasis (A). The number of metastatic lesions in the lung was
determined for each group of injected mice (B). *, P  0.0001.
FIG. 6. Determination of MMP-9 activity in conditioned media from ATC cell lines. Conditioned media from parental and infected BHT101 (A, *,
P  0.001, **, P  0.0001) and Act1 (C, *, P  0.001, **, P  0.0001) cell lines were collected to determine the concentration of active MMP-9.
qRT-PCR analysis showed that no difference of MMP-9 expression was detected among cell lines (B and D).
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were grown in serum-free medium, and after 48 h their
conditioned media were collected to measure the levels of
endogenous active MMP-9. As shown in Fig. 6A, the ab-
sence of NGAL in BHT101 cells determined a strong de-
crease of activeMMP-9 content compared with that mea-
sured in the extracellular medium of parental and
scrambled BHT101 cells. On the contrary, the concentra-
tion of active MMP-9 from the conditioned medium of
NGAL-overexpressingBHT101 cellswas higher than that
from conditioned media of control cells (Fig. 6C). Impor-
tantly, the presence of the mutated form of NGAL in
BHT101 extracellular medium had no effect on MMP-9
activity. The up- or down-regulation of enzymatic activity
in the different experimental systems was not dependent
on MMP-9 expression because RT-PCR analysis showed
that no differences of MMP-9 mRNA levels were detect-
able in the various cell lines (Fig. 6, B and D).
Discussion
In the present paper, we analyzed the role of NGAL in
promoting ATC tissue invasion through enhancement of
MMP-9 activity. The inhibition of NGAL expression,
which is strongly elevated in the same primary human
ATC showing high MMP-9 expression, decreases the in
vitro and in vivometastatic potential of BHT101ATCcell
line. This effect is the consequence of the reduced enzy-
matic activity of MMP-9 in the absence of NGAL. How-
ever, knocking downNGAL expression in BHT101 cells
does not completely abrogate the ability of these cells to
invade matrigel and to form lung metastasis (Figs. 4, A
and D, and 5, A and B). This is probably due to the
presence of a residual NGAL expression in BHT siRNA
cells, as assessed by Western blot (Fig. 2A), that still
preserves MMP-9 from autodegradation, as proven by
the partial but not absolute decrease of MMP-9 enzy-
matic activity in the extracellular medium of BHT
NGAL-null cells (Fig. 6A).
The importance of NGAL as regulator of ATC cells
metastatic potential is further supported by increased
MMP-9 enzymatic activity in the Act1 after ectopic ex-
pression of NGAL. In this case, the secretion of extracel-
lular NGAL improves the MMP-9 enzymatic activity of
Act1 cells causing the increased invasion throughmatrigel
in the transwell assay. This effect is clearly NGAL medi-
ated because Act1 cells overexpressing the C87R mutant
of NGAL show aMMP-9 activity and an invasive behav-
ior similar to those of control cells. The evidence of a basal
MMP-9 activity independent ofNGALexpression inAct1
cells (Figs. 4,D andE, and 6C) points out thatMMP-9 can
function in the absence of NGAL; even so, the presence of
NGAL significantly improves its enzymatic activity.
In the light of these findings, the strong coexpression of
NGAL and MMP-9 in primary human ATC suggests a
pro-metastatic role of NGAL/MMP-9 complex in aggres-
sive thyroid carcinomas. Anaplastic thyroid carcinomas
constitute themost undifferentiated type of thyroid cancer
withmarked invasive properties so that the presence of an
active NGAL/MMP-9 complex could explain in part the
metastatic potential of ATC cells. The biological impor-
tance of NGAL/MMP-9 complex in cancer has been ex-
tensively studied in other human tumors, such as breast
cancer (18, 23), esophageal (20) and oral (24, 25) squa-
mous cell carcinomas, cholangiocarcinomas (21), bladder
cancer (26), gastric cancer (19), and rectal cancer (27). In
these reports the activity of the complex generally corre-
lates with the more aggressive behavior of neoplastic cells
and, in themajority of cases, with a poor prognosis. Thus,
the role of NGAL/MMP-9 complex in metastatic thyroid
cancer, up to nownot yet elucidated, fits with that exerted
in other types of human tumors.
The identification of NGAL as a regulator of ATC-
induced metastasis adds a novel piece to the puzzle of
NF-B functions in thyroid cancer (10, 11, 28–31). In fact,
our previous results and the findings reported here indi-
cate that NF-B activity could influence the invasive po-
tential of ATC cells through the up-regulation of NGAL
other than ofMMP-9, whosemRNA transcription, as it is
known, is in part under NF-B control (32). This could
also explain why the expression of both genes is so ele-
vated inATCs inwhichNF-B is strongly activated. In this
way, NGAL could be viewed as a novel target gene of
NF-B-mediated metastatic activity of ATC cells and its
inhibitionas apotential tool for therapeutical intervention
in advanced ATC therapy without altering NF-B physi-
ological functions.
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